Blueprint Medicines Corp’s recent filing unveils that its PRESIDENT, R & D Namouni Fouad unloaded Company’s shares for reported $0.32 million on Oct 03 ’24. In the deal valued at $89.32 per share,3,633 shares were sold. As a result of this transaction, Namouni Fouad now holds 69,070 shares worth roughly $5.72 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Albers Jeffrey W. sold 19,702 shares, generating $1,685,891 in total proceeds. Upon selling the shares at $85.57, the Director now owns 157,557 shares.
Before that, Albers Jeffrey W. bought 19,702 shares. Blueprint Medicines Corp shares valued at $1,685,911 were divested by the Director at a price of $85.57 per share.
UBS initiated its Blueprint Medicines Corp [BPMC] rating to a Neutral in a research note published on October 24, 2024; the price target was $88. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid May with a ‘”an Overweight”‘ rating. Leerink Partners also remained covering BPMC and has increased its forecast on May 06, 2024 with a “Market perform” recommendation from previously “an Underperform” rating. Oppenheimer revised its rating on October 27, 2023. It rated BPMC as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BPMC
On Monday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 0.36% to $82.77. Over the last five days, the stock has lost -3.32%. Blueprint Medicines Corp shares have fallen nearly -10.27% since the year began. Nevertheless, the stocks have risen 49.89% over the past one year. While a 52-week high of $121.90 was reached on 07/16/24, a 52-week low of $47.66 was recorded on 02/14/24. SMA at 50 days reached $89.29, while 200 days put it at $94.78.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 81.41, which if violated will result in even more drops to 80.06. On the upside, there is a resistance level at 84.38. A further resistance level may holdings at 86.00. The Relative Strength Index (RSI) on the 14-day chart is 34.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.41%. Stochastics %K at 15.66% indicates the stock is a buying.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2024-10-15, dropping by 47542.0 shares to a total of 3.62 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 3.67 million shares. There was a decline of -1.31%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 21, 2023 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $66.
